… In EGFR-positive lung cancer subpopulations, data from Phase III trials suggest that reversible
EGFR-TKI efficacy varies according to EGFR mutation subtype with a trend toward higher …

… EGFR tyrosine kinase mutations [6, 7]. The identification of EGFR mutations leads to the
development of EGFR … confirmed EGFR mutation and patients with unknown or EGFR wild-type. …

… to treat lung cancer worldwide, but the survival rate has not been significantly improved.
The discovery of EGFR mutations and the advent of EGFR-tyrosine kinase inhibitors (EGFR-TKIs…

… (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are
standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC…

… Since 2004, several important trials have established EGFR tyrosine kinase inhibitor (TKI)
therapy as the standard first-line care for patients with EGFR mutations (3–5). First-generation …

… –small cell lung cancer who achieve dramatic clinical and radiographic response to the
EGFR tyrosine kinase inhibitors (TKI) gefitinib and erlotinib. These mutations in EGFR are found …

… -TK activity plays a restricted role in skin and gastrointestinal tract cancers, suggesting an
EGFR inhibition mechanism for such effects [31–33]. These adverse effects may be common to …

… confirmed as predictors of efficacy for EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Gefitinib
… the most updated results of these studies to better quantify the clinical benefits of EGFR-TKI …

… Nevertheless, rigorous quantitative analysis of differences in efficacy outcomes according
to clinical subgroups based on an updated systematic review of randomized control trials of …

… harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to
EGFR tyrosine kinase inhibitors (TKI). In these patients, acquired resistance to …